Clinical trials: Schizophrenia Diagnosis
Schizophrenia
A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose
The purposes of this study are to investigate the metabolic pathways of paliperidone and excretion of paliperidone and its metabolites in healthy adult male volunteers, both CYP2D6 poor and extensive metabolizers, after…
- Trial name
- NCT00796029
- Testing
- 14C-paliperidone
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Post Traumatic Stress Disorder, Alcohol Use Disorder
FAAH Availability in Psychiatric Disorders: A PET Study
The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system…
- Conditions
- Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis
- Trial name
- NCT04404712
- Testing
- [11C]MK-3168
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Psychotic Disorders
Enhancing the Prospective Prediction of Psychosis
This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.
- Trial name
- NCT00291200
- Where
- 3 sites in United States, Canada
- Volunteers
- 268 people
- Sponsor
- Yale University
Psychosis
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset.
- Trial name
- PSYCARE (NCT05796401)
- Testing
- Cognitive training, Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC, Treatment as usual (TAU)
- Where
- 13 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier St Anne
Prodromal Schizophrenia
Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis
Onset of psychotic disorders such as schizophrenia, typically occurs during late adolescence or early adulthood often resulting in chronic social and occupational disability.
- Trial name
- NCT01619319
- Testing
- Cognitive Remediation Therapy, computer games
- Volunteers
- 32 people
- Sponsor
- University of Calgary
Schizophrenia
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02281773
- Testing
- BI 409306 100 mg QD, BI 498306 50 mg QD, BI 498306 25 mg QD
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 518 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic
This trial attempts to evaluate the effects of intensive transcranial direct-current stimulation (tDCS) on improving cognition in schizophrenia patients and changes in resting state brain network connectivity, especially…
- Trial name
- NCT02748083
- Testing
- tDCS
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Bipolar Disorder
Task Sharing for the Care of Severe Mental Disorders in a Low-income Country
Task sharing mental health care through integration of mental health into primary health care (PHC) is advocated as a means of narrowing the treatment gap for mental disorders in low-income countries.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- TaSCS (NCT02308956)
- Testing
- Integrated mental health in primary care, Psychiatric nurse-led specialist care
- Where
- Ethiopia
- Volunteers
- 324 people
- Sponsor
- University of Cape Town
Schizophrenia
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
Background: The aims of this study were to explore the relationship between early reduction in psychotic symptoms and the ultimate response in patients with schizophrenia treated by atypical antipsychotics, and to determine the…
- Trial name
- NCT03730857
- Testing
- Olanzapine, risperidone, Paliperidone
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Calo Psychiatric Center
Schizophrenia Spectrum Disorders, Negative Symptoms in Schizophrenia
ENGAGE: Virtual Reality-based Psychotherapy for Negative Symptoms in Schizophrenia
The primary goal of this pilot study is to examine the feasibility and acceptability of a new Virtual Reality-based intervention against negative symptoms in schizophrenia spectrum disorders (SSD).
- Trial name
- ENGAGE (NCT06993831)
- Testing
- Virtual Reality-based psychotherapy
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Treatment, Active Control
Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)
Primary study: This study is a single-site, double-blind, randomized, controlled clinical trial to compare an evidence-based structured program of 30-35 hours of on-line cognitive and social cognitive training exercises performed…
- Conditions
- Treatment, Active Control, Schizophrenia, Psychosis
- Trial name
- NCT02782442
- Testing
- Structured Cognitive Training & PRIME, Computer Games Control & PRIME
- Where
- 2 sites in United States
- Volunteers
- 109 people
- Sponsor
- University of Minnesota
Safety and Tolerability of Iloperidone
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication
- Trial name
- NCT01495169
- Testing
- iloperidone (oral tablet)
- Where
- 10 sites in United States
- Volunteers
- 33 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Schizoaffecitve Disorder
Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder
The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue…
- Trial name
- NCT07755605
- Testing
- Digital therapeutic (AffectUs), Psychoeducational materials
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia
Current medications have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline which has a beneficial effect in various neurological…
- Trial name
- NCT02907437
- Testing
- Minocycline, Probiotics
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Beer Yaakov - Ness Ziona Mental Health Center
Schizophrenia
Efficacy of Metacognitive Training for Schizophrenia - a Study Protocol
Metacognitive training (MCT) for schizophrenia has been used in several countries, but its efficacy remains unclear. MCT is a program group that consists of changing the cognitive infrastructure of delusions.
- Trial name
- NCT03891186
- Testing
- Metacognitive Training in Schizophrenia (MCT), Treatment As Usual (TAU)
- Where
- Portugal
- Volunteers
- 60 people
- Sponsor
- University Rovira i Virgili
Psychotic Disorder, Schizophrenia
Gut Microbiome in AP Naive
Antipsychotic (AP) medications are currently the cornerstone of treatment for schizophrenia (SCZ), with off-label prescription rapidly increasing in youth, with an established two-fold increase in standardized mortality ratio…
- Trial name
- NCT03414151
- Testing
- Observation
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Centre for Addiction and Mental Health
Ultra High Risk for Psychosis
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
The purpose of this study is to determine whether omega-3 fatty acids are effective in the prevention of psychosis in individuals at ultra-high risk for psychosis.
- Trial name
- PURPOSE (NCT02597439)
- Testing
- Omega-3 fatty acids
- Where
- 14 sites in Austria, Germany and 7 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Rene Kahn
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.